Please assess the completion status of the following clinical trial:

Trial Title: Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18 years~* Patients with COVID-19 (positive COVID PCR)~* Use of intubation for mechanical ventilation~Exclusion Criteria:~* Use of Extracorporeal Membrane Oxygenation~* Treatment with Tocilizumab (anti-Il6)~* Pregnant woman~* Patients under protective administration or deprived of liberty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with COVID-19 acute respiratory distress syndrome (Type: OTHER): Patients with acute respiratory distress syndrome due to COVID-19 and requiring mechanical ventilation

Based on this trial design, predict the completion outcome and termination type (if applicable).